Clinical trial

The Effects of RPL554 in Addition to Tiotropium in COPD Patients

NCT03028142

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-01-01

PhasePHASE2

Study timeline

Study start (unknown)2017-01-01Date precision: month

Registry last updated2019-02-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Obstructive Pulmonary Disease Moderateunresolved

Interventions

1.5 mg RPL554 plus tiotropiumDRUG

6 mg RPL554 plus tiotropiumDRUG

Placebo plus tiotropiumDRUG

Sponsors & collaborators

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03028142 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.